Meeting
2020 Genitourinary Cancers Symposium
A pilot study of tazemetostat and MK-3475 (pembrolizumab) in advanced urothelial carcinoma (ETCTN 10183).
Authors
Joshua J. Meeks
Jesse Brown VAMC, Northwestern University, Feinberg School of Medicine, Chicago, IL
Joshua J. Meeks , Ali Shilatifard , Stephen D. Miller , Alicia K. Morgans , David James VanderWeele , Masha Kocherginsky , Maha H. A. Hussain
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Translational Research
Clinical Trial Registration Number
NCT03854474
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS607)
Abstract #
TPS607
Poster Bd #
P3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).
First Author: Maha H. A. Hussain
Poster
2024 ASCO Annual Meeting
A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).
First Author: Maha H. A. Hussain
Poster
2021 ASCO Annual Meeting
Immunotherapy in combination with PARP inhibition in advanced cervical cancer patients functionally competent or deficient for the Fanconi anemia repair pathway.
First Author: John Paul Diaz
Poster
2020 ASCO Virtual Scientific Program
Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.
First Author: Marjorie Glass Zauderer